Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (STRENGTH)
Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ
Published in JAMA
Methodology
Double-blind randomized trial of 4 g/day carboxylic acid formulation of EPA/DHA vs corn oil in statin-treated high-risk patients; terminated early for futility
Key Findings
Primary composite endpoint occurred in 12.0% of the omega-3 group vs 12.2% of corn oil (HR 0.99, 95% CI 0.90-1.09); atrial fibrillation was more frequent with omega-3 (2.2% vs 1.3%).
Conclusions
High-dose mixed EPA/DHA did not reduce major adverse cardiovascular events compared with corn oil, contrasting with REDUCE-IT.
Limitations
Early termination for futility; comparator differences with REDUCE-IT complicate interpretation.
Supplements Studied
Among statin-treated patients at high cardiovascular risk, the addition of omega-3 CA, compared with corn oil, resulted in no significant difference in a composite outcome of major adverse cardiovascular events.
Outcomes Measured
Primary composite endpoint occurred in 12.0% of the omega-3 group vs 12.2% of corn oil (HR 0.99, 95% CI 0.90-1.09); atrial fibrillation was more frequent with omega-3 (2.2% vs 1.3%).
The addition of omega-3 carboxylic acids resulted in no significant difference in major adverse cardiovascular events.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
AstraZeneca
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.